SSI potentially contaminated surgery SSI Assessment method: various clinical measures · surgical wounds resulting from a range of surgical procedures with some risk of contamination healing by primary intention
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Potential adverse effects ‐ not reported · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in mean compound muscle action potential amplitude after 4 weeks mA. Scale from: 0 to 10. · people with CIDP
1 finding from 1 review
Intervention not reported
Potentially harmful ADEs
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Potential ADEs
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Potentially harmful MEs
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intervention not reported
Health workers' resuscitation practices: inappropriate and potentially harmful practices per resuscitation Direct observation Scale: 0 to 1 (better indicated by lower values) · nurses and midwives
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Somatosensory evoked potentials · Patients of any age in any setting requiring intervention for iatrogenic injury to the inferior alveolar or lingual nerve
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
After accounting for all potential confounders, the overall average effect of speed cameras on crashes was a reduction of 25% in personal injury crashes (PIA's) and an average 11% reduction in fatal and serious crashes for the 500m monitoring leng...
1 finding from 1 review
no estimate extracted
Studies not reported
High
Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab probably leads to lower infection with SARS‐CoV‐2 within 6 months compared with placebo (moderate certainty).
1 finding from 1 review
Infection with SARS‐CoV‐2 within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower infection with SARS‐CoV‐2 within 6 monthsa compared with placebo (low certainty).
1 finding from 1 review
Development of clinical COVID‐19 symptoms within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab may leads to lower development of clinical COVID‐19 symptoms within 6 months compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
1 finding from 1 review
Change in hospital admission rates · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life at longest · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events: grade 1 to 2 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
It is very uncertain whether casirivimab/imdevimab changes adverse events: grade 3 to 4 within 6 months compared with placebo (very low certainty).
2 findings from 1 review
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in adverse events: all grades within 6 months compared with placebo (low certainty).
2 findings from 1 review
Serious adverse events within 6 months · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
It is very uncertain whether casirivimab/imdevimab changes serious adverse events within 6 months compared with placebo (very low certainty).
1 finding from 1 review
Outcomes · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found